36 related articles for article (PubMed ID: 17311702)
1. Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects.
Munker S; Gerken M; Fest P; Ott C; Schnoy E; Fichtner-Feigl S; Wiggermann P; Vogelhuber M; Herr W; Stroszczynski C; Schlitt HJ; Evert M; Reng M; Klinkhammer-Schalke M; Teufel A
BMC Cancer; 2018 Apr; 18(1):455. PubMed ID: 29685155
[TBL] [Abstract][Full Text] [Related]
2. High-accuracy prediction of colorectal cancer chemotherapy efficacy using machine learning applied to gene expression data.
Amniouel S; Jafri MS
Front Physiol; 2023; 14():1272206. PubMed ID: 38304289
[No Abstract] [Full Text] [Related]
3. Discovery of dihydrooxazolo[2,3-
Ding L; Wang L; Zou K; Li B; Song Y; Zhang Q; Zhao Y; Xu Z; Ge G; Zhao B; Zhu W
RSC Adv; 2019 Oct; 9(61):35904-35912. PubMed ID: 35528066
[TBL] [Abstract][Full Text] [Related]
4. Impact of
Keum J; Lee HS; Jo JH; Chung MJ; Park JY; Park SW; Song SY; Bang S
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267552
[TBL] [Abstract][Full Text] [Related]
5. Lactobacillus Kefiri LKF01 (Kefibios
Ghidini M; Nicoletti M; Ratti M; Tomasello G; Lonati V; Ghilardi M; Parati MC; Borgonovo K; Cabiddu M; Petrelli F
Nutrients; 2021 Jan; 13(2):. PubMed ID: 33513713
[TBL] [Abstract][Full Text] [Related]
6. Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab.
Lim HH; Hopkins AM; Rowland A; Yuen HY; Karapetis CS; Sorich MJ
Target Oncol; 2019 Dec; 14(6):743-748. PubMed ID: 31676953
[TBL] [Abstract][Full Text] [Related]
7. Differences in UGT1A1, UGT1A7, and UGT1A9 polymorphisms between Uzbek and Japanese populations.
Maeda H; Hazama S; Shavkat A; Okamoto K; Oba K; Sakamoto J; Takahashi K; Oka M; Nakamura D; Tsunedomi R; Okayama N; Mishima H; Kobayashi M
Mol Diagn Ther; 2014 Jun; 18(3):333-42. PubMed ID: 24453052
[TBL] [Abstract][Full Text] [Related]
8. Diamine oxidase as a marker of intestinal mucosal injury and the effect of soluble dietary fiber on gastrointestinal tract toxicity after intravenous 5-fluorouracil treatment in rats.
Fukudome I; Kobayashi M; Dabanaka K; Maeda H; Okamoto K; Okabayashi T; Baba R; Kumagai N; Oba K; Fujita M; Hanazaki K
Med Mol Morphol; 2014 Jun; 47(2):100-7. PubMed ID: 24005798
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer: an assessment of safety and efficacy in the province of Newfoundland and Labrador.
Dranitsaris G; Edwards S; Edwards J; Leblanc M; Abbott R
Curr Oncol; 2010 Oct; 17(5):12-6. PubMed ID: 20975873
[TBL] [Abstract][Full Text] [Related]
10. Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer.
Eng C
Nat Rev Clin Oncol; 2009 Apr; 6(4):207-18. PubMed ID: 19333227
[TBL] [Abstract][Full Text] [Related]
11. Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy.
Keefe DM; Elting LS; Nguyen HT; Grunberg SM; Aprile G; Bonaventura A; Selva-Nayagam S; Barsevick A; Koczwara B; Sonis ST
Cancer Chemother Pharmacol; 2014 Oct; 74(4):675-80. PubMed ID: 25055935
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
14. [IFL].
Yamazaki K; Yoshino T; Boku N
Gan To Kagaku Ryoho; 2006 Jul; 33(7):907-10. PubMed ID: 16835478
[TBL] [Abstract][Full Text] [Related]
15. Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool.
Dranitsaris G; Shah A; Spirovski B; Vincent M
Clin Colorectal Cancer; 2007 Jan; 6(5):367-73. PubMed ID: 17311702
[TBL] [Abstract][Full Text] [Related]
16. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
